Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Common Stock | Options Exercise | $3.26M | +127K | +24.32% | $25.60 | 650K | Feb 26, 2022 | Direct | F1 |
transaction | PFE | Common Stock | Tax liability | -$1.65M | -34.6K | -5.32% | $47.72 | 615K | Feb 26, 2022 | Direct | F2, F3 |
transaction | PFE | Common Stock | Tax liability | -$3.01M | -59.4K | -9.65% | $50.64 | 556K | Feb 26, 2022 | Direct | F4, F5 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -127K | -100% | $0.00* | 0 | Feb 26, 2022 | Common Stock | 127K | $25.60 | Direct |
Id | Content |
---|---|
F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
F3 | Price is the closing price of Pfizer common stock on February 25, 2022. |
F4 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
F5 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |